NLTX 13.96 (+1.45%)
US64049K1043Drug ManufacturersDrug Manufacturers - Specialty & Generic

Neoleukin Therapeutics (NLTX) Financial Metrics

This table shows a selected set of financial data points of Neoleukin Therapeutics (NLTX). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2022 -1.04 0 -9.77 562.46M -0.41 0 -46.72M -56.49M -57.56M 37.89M
2021 -1.1 0 -87.42 5.31B -0.32 0 -50.82M -60.7M -60.69M 142.47M
2020 -0.64 0 -439.18 14.61B -0.19 0 -26.79M -47.56M -33.28M 192.56M
2019 -2.57 0 -95.91 6.66B -0.62 0 -16.27M -21.37M -69.44M 143.09M
2018 -1.34 0 -32.17 1.02B -0.34 25M -31.63M -31.58M -31.59M 76.93M
2017 -2.14 0 -109.91 5.52B -0.38 0 -45.21M -50.18M -50.18M 52.03M
2016 -1.96 0 -168.61 6.24B -0.28 0 -30.94M -37M -37M 32.3M
2015 -1.73 0 -144.3 3.15B -0.28 0 -20.3M -21.76M -21.86M 39.53M
2014 -2.77 0 -54.11 1.3B -0.84 0 -17.92M -23.43M -24.03M 14.91M
2013 -1.49 0 0 0 -0.97 0 -7.95M -8.63M -8.73M 11.01M
2012 -1.32 0 0 0 0 0 -7.24M -7.53M -7.71M 2M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.